Dyno Therapeutics Announces Ocular Collaboration With Novartis To Develop Improved Gene Therapies With Aav Vectors Based On Ai Technology
Dyno Therapeutics, A Biotechnology Company Applying Artificial Intelligence (Ai) To Gene Therapy, Today Announced A Collaboration With Novartis To Develop Improved Adeno-Associated Virus (Aav) Vectors For Research, Development, And Commercialization Of Gene Therapies For Ocular Diseases. The Partnership Will Allow The Parties To Utilize Dyno&Rsquo;S Capsidmap&Trade; Artificial Intelligence Platform Along With Novartis Expertise In Gene Therapy Development And Global Commercialization To Deliver Innovative Gene Therapies To Patients With Serious Diseases Of The Eye.&Ldquo;We Are Delighted To Be Collaborating With Novartis,&Rdquo; Stated Eric D. Kelsic, Ph.D., Ceo And Co
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!